Novel Norovirus Strain, United States | CDC EID > Volume 17, Number 8–August 2011

full-text ►Novel Norovirus Strain, United States | CDC EID: "EID Journal Home > Volume 17, Number 8–August 2011
Volume 17, Number 8–August 2011
Dispatch
Novel GII.12 Norovirus Strain, United States, 2009–2010

Everardo Vega and Jan Vinjé Comments to Author
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Suggested citation for this article

Abstract
In October 2009, a novel GII.12 norovirus strain emerged in the United States and caused 16% of all reported norovirus outbreaks during the winter season. Sequence analysis demonstrated a recombinant virus with a P2 region that was largely conserved compared with previously sequenced GII.12 strains.

Noroviruses are the leading cause of viral gastroenteritis outbreaks in the United States (1). Over the past decade most norovirus outbreaks have been caused by genogroup (G) II.4 noroviruses, while each of the other genotypes did not cause >7% of the outbreaks (2,3). However, previous studies have suggested that non-GII.4 noroviruses have been predominant in the past (3,4). For example, analysis of archived samples from 1974 through 1991 has shown that the frequency of GII.3 was 48% compared with 16% for GII.4 and 14% for GII.7 strains (3). Therefore, it is essential to study sudden increases of non-GII.4 strains to determine possible signatures that could be associated with increased transmissibility or population susceptibility. In this article, we describe the emergence of a novel GII.12 strain in the United States in the winter of 2009–10 that was associated with a large number of the norovirus outbreaks.

- Enviado mediante la barra Google"

Suggested Citation for this Article

Vega E, Vinjé J. Novel GII.12 norovirus strain, United States, 2009–2010. Emerg Infect Dis [serial on the Internet]. 2011 Aug [date cited]. http://www.cdc.gov/EID/content/17/8/110025.htm

DOI: 10.3201/eid1708.110025

Comments to the Authors

Please use the form below to submit correspondence to the authors or contact them at the following address:

Everardo Vega, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop G04, Atlanta, GA 30333, USA; email: evega@cdc.gov